{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:56:36Z","timestamp":1773276996310,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00261-017-1050-6","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T11:42:54Z","timestamp":1486122174000},"page":"1721-1733","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biliary and pancreatic complications of molecular targeted therapies in cancer imaging"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-1284","authenticated-orcid":false,"given":"Francesco","family":"Alessandrino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sree Harsha","family":"Tirumani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Braschi-Amirfarzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyothi P.","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald N.","family":"Di Salvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"issue":"9916","key":"1050_CR1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","volume":"383","author":"D Hanahan","year":"2014","unstructured":"Hanahan D (2014) Rethinking the\u00a0war\u00a0on\u00a0cancer. Lancet 383(9916):558\u2013563","journal-title":"Lancet"},{"issue":"2","key":"1050_CR2","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","volume":"17","author":"V Prasad","year":"2016","unstructured":"Prasad V, Fojo T, Brada M (2016) Precision\u00a0oncology: origins, optimism, and potential. Lancet Oncol 17(2):e81\u2013e86","journal-title":"Lancet Oncol"},{"key":"1050_CR3","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. Novel drugs approval for 2015. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugInnovation\/ucm430302.htm Page created 01 Apr 2016. Accessed 01 Dec 2016"},{"issue":"12","key":"1050_CR4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ncpgasthep1277","volume":"5","author":"M Davila","year":"2008","unstructured":"Davila M, Bresalier RS (2008) Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 5(12):682\u2013696","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"1","key":"1050_CR5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2214\/AJR.11.7432","volume":"199","author":"SAH Howard","year":"2012","unstructured":"Howard SAH, Krajewski KM, Thornton E, et al. (2012) Decade of molecular targeted therapy: Abdominal manifestations of drug toxicities\u2014What radiologists should know. AJR 199(1):58\u201364","journal-title":"AJR"},{"issue":"6","key":"1050_CR6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10140-012-1052-1","volume":"19","author":"SA Chikarmane","year":"2012","unstructured":"Chikarmane SA, Khurana B, Krajewski KM, et al. (2012) What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents. Emerg Radiol 19(6):535\u2013546","journal-title":"Emerg Radiol"},{"issue":"1018","key":"1050_CR7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1259\/bjr\/19815818","volume":"85","author":"E Thornton","year":"2012","unstructured":"Thornton E, Howard SA, Jagannathan J, et al. (2012) Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 85(1018):1420\u20131426","journal-title":"Br J Radiol"},{"issue":"5","key":"1050_CR8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pan.2013.08.001","volume":"13","author":"SH Tirumani","year":"2013","unstructured":"Tirumani SH, Jagannathan JP, Shinagare AB, et al. (2013) Acute pancreatitis associated with molecular targeted therapies: a retrospective review of the clinico-radiological features, management and outcome. Pancreatology 13(5):461\u2013467","journal-title":"Pancreatology"},{"issue":"1","key":"1050_CR9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1148\/radiol.2016152547","volume":"281","author":"AB Shinagare","year":"2016","unstructured":"Shinagare AB, Steele E, Braschi-Amirfarzan M, Tirumani SH, Ramaiya NH (2016) Sunitinib-associated pancreatic\u00a0atrophy\u00a0in patients with gastrointestinal stromal tumor: a toxicity with prognostic implications detected at imaging. Radiology 281(1):140\u2013149","journal-title":"Radiology"},{"issue":"2","key":"1050_CR10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jss.2015.04.035","volume":"199","author":"L Xu","year":"2015","unstructured":"Xu L, Zhou DS, Zhao J, et al. (2015) Long-term therapy with sorafenib is associated with pancreatic atrophy. J Surg Res 199(2):314\u2013321","journal-title":"J Surg Res"},{"issue":"1","key":"1050_CR11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clinimag.2013.08.012","volume":"38","author":"SH Tirumani","year":"2014","unstructured":"Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH (2014) Gallbladder\u00a0complications\u00a0associated\u00a0with\u00a0molecular targeted therapies:\u00a0clinical\u00a0and\u00a0imaging\u00a0features. Clin Imaging 38(1):50\u201355","journal-title":"Clin Imaging"},{"issue":"1","key":"1050_CR12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.dld.2007.11.016","volume":"41","author":"S Delis","year":"2009","unstructured":"Delis S, Triantopoulou C, Bakoyiannis A, et al. (2009) Sclerosing\u00a0cholangitis in the era of target chemotherapy: a possible anti-VEGF effect. Dig Liver Dis 41(1):72\u201377","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1050_CR13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.mcg.0000173929.60115.b4","volume":"39","author":"CD Trivedi","year":"2005","unstructured":"Trivedi CD, Pitchumoni CS (2005) Drug-induced pancreatitis: an update. J Clin Gastroenterol 39(8):709\u2013716","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"1050_CR14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. N Engl J Med 354(7):731\u2013739","journal-title":"N Engl J Med"},{"issue":"6","key":"1050_CR15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s13244-015-0436-7","volume":"6","author":"D Ngo","year":"2015","unstructured":"Ngo D, Jia JB, Green CS, Gulati AT, Lall C (2015) Cancer\u00a0therapy\u00a0related complications in the liver, pancreas, and biliary system: an\u00a0imaging\u00a0perspective. Insights Imaging 6(6):665\u2013677","journal-title":"Insights Imaging"},{"issue":"1","key":"1050_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/radiol.10092129","volume":"258","author":"JM Torrisi","year":"2011","unstructured":"Torrisi JM, Schwartz LH, Gollub MJ, et al. (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41\u201356","journal-title":"Radiology"},{"issue":"4","key":"1050_CR17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinimag.2008.10.029","volume":"33","author":"NJ Khoury","year":"2009","unstructured":"Khoury NJ, Kanj V, Abboud M, et al. (2009) Abdominal complications of chemotherapy in pediatric malignancies: imaging findings. Clin Imaging 33(4):253\u2013260","journal-title":"Clin Imaging"},{"issue":"3","key":"1050_CR18","first-page":"311","volume":"77","author":"DE Gerber","year":"2008","unstructured":"Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77(3):311\u2013319","journal-title":"Am Fam Physician"},{"issue":"suppl","key":"1050_CR19","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/jco.2015.33.15_suppl.3010","volume":"33","author":"JH Sampson","year":"2015","unstructured":"Sampson JH, Vlahovic G, Sahebjam S, et al. (2015) Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J Clin Oncol 33(suppl):3010","journal-title":"J Clin Oncol"},{"issue":"5","key":"1050_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1592\/phco.27.5.775","volume":"27","author":"Lopes G Lima De","year":"2007","unstructured":"De Lima Lopes G, Rocha Lima CM Jr (2007) Emphysematous cholecystitis in a patient with gastrointestinal stromal tumor treated with sunitinib. Pharmacotherapy 27(5):775\u2013777","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1050_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4081\/cp.2014.635","volume":"4","author":"L Gomes","year":"2014","unstructured":"Gomes L, Fonseca D, Barroso-Sousa R, Sabbaga J, Hoff PM (2014) Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Pract 4(1):635","journal-title":"Clin Pract"},{"key":"1050_CR22","doi-asserted-by":"crossref","first-page":"201529","DOI":"10.5402\/2011\/201529","volume":"2011","author":"M Sanda","year":"2011","unstructured":"Sanda M, Tamai H, Deguchi H, et al. (2011) Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. ISRN Gastroenterol 2011:201529","journal-title":"ISRN Gastroenterol"},{"issue":"5","key":"1050_CR23","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.clinre.2013.04.002","volume":"37","author":"MA Ozturk","year":"2013","unstructured":"Ozturk MA, Kalayci M, Oyan B (2013) Gallbladder perforation related to bevacizumab. Clin Res Hepatol Gastroenterol 37(5):e117\u2013e118","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1050_CR24","unstructured":"eHealthMe -Real World Drug Outcomes. Could Avastin cause Gallbladder perforation? http:\/\/www.ehealthme.com\/ . Page created 05 June 2013. Accessed 20 Oct 2016"},{"key":"1050_CR25","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1200\/JCO.2003.99.046","volume":"21","author":"S Kilickap","year":"2003","unstructured":"Kilickap S, Abali H, Celik I (2003) Bevacizumab, bleeding, thrombosis and warfarin. J Clin Oncol 21:3542","journal-title":"J Clin Oncol"},{"key":"1050_CR26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-13-242","volume":"13","author":"LS Rosen","year":"2013","unstructured":"Rosen LS, Lipton L, Price TJ, et al. (2013) The effect of different dosing regimens of\u00a0motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer 13:242","journal-title":"BMC Cancer"},{"key":"1050_CR27","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. Afinitor (everolimus) Tablets. Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm258494.htm . Page created 07 July 2016. Accessed 06 Oct 2016"},{"issue":"2","key":"1050_CR28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdp558","volume":"21","author":"F Pantano","year":"2010","unstructured":"Pantano F, Santini D, Guida F, Vincenzi B, Tonini G (2010) Potential role of everolimus in inducing cholestasis. Ann Oncol 21(2):433","journal-title":"Ann Oncol"},{"key":"1050_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1600-0773.2001.d01-147.x","volume":"89","author":"S Bramow","year":"2001","unstructured":"Bramow S, Ott P, Thomsen Nielsen F, et al. (2001) Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 89:133\u2013139","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"1050_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2005.00476.x","volume":"75","author":"M Breccia","year":"2005","unstructured":"Breccia M, D\u2019Andrea M, Alimena G (2005) Can\u00a0nifedipine\u00a0and\u00a0estrogen\u00a0interaction with\u00a0imatinib\u00a0be\u00a0responsible\u00a0for\u00a0gallbladder\u00a0stone\u00a0development? Eur J Haematol 75(1):89\u201390","journal-title":"Eur J Haematol"},{"key":"1050_CR31","unstructured":"U. S. Food and Drug Administration\/Center for Drug Evaluation and Research. Gleevec (imatinib mesylate)\u2014Revised product label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/021588s009lbl.pdf Page created 30 Oct 2006. Accessed 01 Dec 2016"},{"issue":"1","key":"1050_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7863\/ultra.33.1.9","volume":"33","author":"C Cooley","year":"2014","unstructured":"Cooley C, Nishino M, Jagannathan J, et al. (2014) Clinical problem solving: Utility of sonography in oncologic patients. J Ultrasound Med 33(1):9\u201322","journal-title":"J Ultrasound Med"},{"issue":"3","key":"1050_CR33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jcu.1870100305","volume":"10","author":"PW Ralls","year":"1982","unstructured":"Ralls PW, Halls J, Lapin SA, et al. (1982) Prospective evaluation of the\u00a0sonographic\u00a0Murphy\u00a0sign\u00a0in suspected acute cholecystitis. J Clin Ultrasound 10(3):113\u2013115","journal-title":"J Clin Ultrasound"},{"issue":"2","key":"1050_CR34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2214\/AJR.05.1712","volume":"188","author":"AC Breda Vriesman Van","year":"2007","unstructured":"Van Breda Vriesman AC, Engelbrecht MR, Smithuis RH, Puylaert JB (2007) Diffuse\u00a0gallbladder\u00a0wall thickening: differential diagnosis. AJR 188(2):495\u2013501","journal-title":"AJR"},{"issue":"4","key":"1050_CR35","doi-asserted-by":"crossref","first-page":"W367","DOI":"10.2214\/AJR.10.4340","volume":"196","author":"OJ O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OJ, Maher MM (2011) Imaging of\u00a0cholecystitis. AJR 196(4):W367\u2013W374","journal-title":"AJR"},{"issue":"4","key":"1050_CR36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1148\/radiographics.20.4.g00jl04959","volume":"20","author":"KM Vitellas","year":"2000","unstructured":"Vitellas KM, Keogan MT, Freed KS, Enns RA, et al. (2000) Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancreatography. Radiographics 20(4):959\u2013975","journal-title":"Radiographics"},{"issue":"11","key":"1050_CR37","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/j.1572-0241.2005.00317.x","volume":"100","author":"NG Venneman","year":"2005","unstructured":"Venneman NG, Buskens E, Besselink MG, et al. (2005) Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy? Am J Gastroenterol 100(11):2540\u20132550","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1050_CR38","first-page":"291","volume":"11","author":"R Pezzilli","year":"2010","unstructured":"Pezzilli R, Corinaldesi R, Morselli-Labate AM (2010) Tyrosine kinase\u00a0inhibitors and acute\u00a0pancreatitis. JOP 11(3):291\u2013293","journal-title":"JOP"},{"issue":"1","key":"1050_CR39","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1345\/aph.1R334","volume":"47","author":"T Engel","year":"2013","unstructured":"Engel T, Justo D, Amitai M, Volchek Y, Mayan H (2013) Nilotinib-associated acute\u00a0pancreatitis. Ann Pharmacother 47(1):e3","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1050_CR40","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2009.010496","volume":"94","author":"F Palandri","year":"2009","unstructured":"Palandri F, Castagnetti F, Soverini S, et al. (2009) Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with\u00a0nilotinib\u00a0after imatinib failure. Haematologica. 94(12):1758\u20131761","journal-title":"Haematologica."},{"key":"1050_CR41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fonc.2014.00067","volume":"4","author":"I Qaddoumi","year":"2014","unstructured":"Qaddoumi I, Kocak M, Pai Panandiker AS, et al. (2014) Phase II Trial of\u00a0Erlotinib\u00a0during and after radiotherapy in children with newly diagnosed high-grade gliomas. Front Oncol 4:67","journal-title":"Front Oncol"},{"key":"1050_CR42","first-page":"755e62","volume":"37","author":"H Akaza","year":"2007","unstructured":"Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase ii study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755e62","journal-title":"Jpn J Clin Oncol"},{"key":"1050_CR43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, et al. (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972","journal-title":"J Clin Oncol"},{"issue":"21","key":"1050_CR44","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516\u20132524","journal-title":"JAMA"},{"issue":"1","key":"1050_CR45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.critrevonc.2014.11.008","volume":"94","author":"P Ghatalia","year":"2015","unstructured":"Ghatalia P, Morgan CJ, Choueiri TK, et al. (2015) Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 94(1):136\u2013145","journal-title":"Crit Rev Oncol Hematol"},{"key":"1050_CR46","doi-asserted-by":"crossref","first-page":"1492e8","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"H Minami","year":"2008","unstructured":"Minami H, Kawada K, Ebi H, et al. (2008) Phase i and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492e8","journal-title":"Cancer Sci"},{"key":"1050_CR47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013209","journal-title":"Eur J Cancer"},{"issue":"4","key":"1050_CR48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384","journal-title":"Lancet Oncol"},{"issue":"10","key":"1050_CR49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, et al. (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with\u00a0ipilimumab. Cancer Immunol Res 3(10):1185\u20131192","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1050_CR50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","volume":"35","author":"JJ Kwak","year":"2015","unstructured":"Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35(2):424\u2013437","journal-title":"Radiographics"},{"issue":"3","key":"1050_CR51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.lungcan.2010.08.004","volume":"70","author":"GM Ruinemans","year":"2010","unstructured":"Ruinemans GM, Balemans C, Mattijssen V, Wiersma-van Tilburg AJ, Smit HJ (2010) Fatal necrotizing\u00a0pancreatitis\u00a0during combined treatment with\u00a0erlotinib\u00a0and sunitinib. Lung Cancer 70(3):364\u2013365","journal-title":"Lung Cancer"},{"key":"1050_CR52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000377681","volume":"89","author":"MK Ganten","year":"2015","unstructured":"Ganten MK, Schuessler M, Bruckner T, Ganten TM, Koschny R (2015) Clinical study pancreatic atrophy in hepatocellular carcinoma patients receiving long-term treatment with Sorafenib. Oncology 89:88\u201394","journal-title":"Oncology"},{"issue":"15","key":"1050_CR53","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMc1305302","volume":"369","author":"S Hescot","year":"2013","unstructured":"Hescot S, Vignaux O, Goldwasser F (2013) Pancreatic\u00a0atrophy\u2013a new late toxic effect of sorafenib. N Engl J Med 369(15):1475\u20131476","journal-title":"N Engl J Med"},{"issue":"6","key":"1050_CR54","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","volume":"28","author":"S Antoun","year":"2010","unstructured":"Antoun S, Birdsell L, Sawyer MB, et al. (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 28(6):1054\u20131060","journal-title":"J Clin Oncol"},{"issue":"4","key":"1050_CR55","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.pan.2013.05.007","volume":"13","author":"MJ Jones","year":"2013","unstructured":"Jones MJ, Buchanan AS, Neal CP, et al. (2013) Imaging of indeterminate pancreatic cystic lesions: a systematic review. Pancreatology 13(4):436\u2013442","journal-title":"Pancreatology"},{"issue":"9","key":"1050_CR56","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00276-012-0962-7","volume":"34","author":"A Djuric-Stefanovic","year":"2012","unstructured":"Djuric-Stefanovic A, Masulovic D, Kostic J, Randjic K, Saranovic D (2012) CT volumetry of normal pancreas: correlation with the pancreatic diameters measurable by the cross-sectional imaging, and relationship with the gender, age, and body constitution. Surg Radiol Anat 34(9):811\u2013817","journal-title":"Surg Radiol Anat"},{"issue":"1","key":"1050_CR57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","volume":"62","author":"PA Banks","year":"2013","unstructured":"Banks PA, Bollen TL, Dervenis C, et al. (2013) Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. Gut 62(1):102\u2013111","journal-title":"Gut"},{"issue":"5","key":"1050_CR58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CMR.0000000000000273","volume":"26","author":"L Kottschade","year":"2016","unstructured":"Kottschade L, Brys A, Peikert T, et al. (2016) A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 26(5):469\u2013480","journal-title":"Melanoma Res"},{"issue":"4 Suppl 2","key":"1050_CR59","first-page":"e1","volume":"13","author":"Working Group IAP\/APA Acute Pancreatitis Guidelines","year":"2013","unstructured":"Working Group IAP\/APA Acute Pancreatitis Guidelines (2013) IAP\/APA\u00a0evidence-based\u00a0guidelines\u00a0for the management of acute pancreatitis. Pancreatology 13(4 Suppl 2):e1\u2013e15","journal-title":"Pancreatology"},{"issue":"5","key":"1050_CR60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2214\/ajr.183.5.1831261","volume":"183","author":"KJ Mortele","year":"2004","unstructured":"Mortele KJ, Wiesner W, Intriere L, et al. (2004) A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome. AJR Am J Roentgenol 183(5):1261\u20131265","journal-title":"AJR Am J Roentgenol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00261-017-1050-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-017-1050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-017-1050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T11:16:37Z","timestamp":1658574997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00261-017-1050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1007\/s00261-017-1050-6","relation":{},"ISSN":["2366-004X","2366-0058"],"issn-type":[{"value":"2366-004X","type":"print"},{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}